Business Wire

Orca Security Offers Best-in-Class Approach to Secure Cloud-Native Applications, Expanding with ThreatOptix’s Agent-Based Runtime Protection

21.2.2023 14:00:00 EET | Business Wire | Press release

Share

Orca Security, the pioneer of agentless cloud security, today announced that the Orca Cloud Security Platform will include ThreatOptix’s agent-based runtime protection and enforcement for cloud-native applications, including virtual machines, containers, and Kubernetes applications. While Orca remains committed to agentless cloud security, this new capability builds on Orca's industry leadership in delivering the most comprehensive coverage and visibility across the cloud estate and offers customers a choice in how they want to secure their applications.

New capabilities from ThreatOptix, whose technology provides comprehensive Linux security with an emphasis on cloud workload protection, will enhance the runtime detection and enforcement within the Orca Cloud Security Platform. The new features in the Orca Platform will be delivered via a strategic partnership with ThreatOptix, where all agent deployments and policy management, as well as data, will be fully integrated into the Orca Platform and sold as a single platform.

Security teams have many challenges in securing modern workloads, including vulnerability management, compliance monitoring, and advanced threat detection and prevention. Orca has been solely focused on delivering best-in-breed agentless capabilities to address these concerns. Yet there are specific mission critical applications where organizations may require an agent for advanced runtime protection and enforcement.

According to Enterprise Strategy Group*, “The growing footprint of Linux-based workloads, both virtual machine instances and application containers, has become a more prominent facet of the attack surface. Because these assets are temporal, they are often not running when security analysts are conducting investigations. As such, capturing system activity with an EDR offering that is purpose-built for Linux workloads is required.”

“At Orca Security, we have a mission to continually innovate cloud security and push the limits of what’s possible to be your key partner for securing the entirety of your cloud environments now and in the future,” said Avi Shua, CEO and co-founder of Orca Security. “As we expand our Cloud Security Platform, we are strategically partnering with ThreatOptix due to their core focus on delivering runtime protection and enforcement for cloud-native applications.”

ThreatOptix was founded by Ehud (“Udi”) Shamir and Sameet Mehta. Udi co-founded the XDR pioneer SentinelOne, where Sameet served as CFO, and both bring years of experience in workload runtime protection.

“At ThreatOptix, we have focused on cloud workload protection from inception,” said Udi Shamir. “The existing EDR solutions are not optimized to address the dynamic and ephemeral nature of modern cloud-native applications that run on containers and Kubernetes. Partnering with Orca, the leader in agentless cloud security, will strengthen an already innovative solution to better address the use cases for deploying an agent for cloud workload protection.”

Upon this integration, Orca Cloud Security Platform customers will be able to immediately deploy and manage the ThreatOptix agent as well as configure policies from the Orca UI. All agent-based runtime telemetry will be fully available within the Orca Unified Data Model to ensure ease-of-use and operation.

“Many partnerships in the cybersecurity ecosystem lack a deep integration strategy. This leads to duct-taped solutions that are inefficient and lack value for their users,” said Gil Geron CPO and co-founder of Orca Security. “We believe this strategic partnership and integration will be transformative for securing the cloud in a purpose-built way to deliver a seamless solution sold under a single SKU. Once integrated, Orca customers will have a seamless experience with the agent acting similarly to a native Orca capability. The Platform will support all cloud environments secured by us today, including highly regulated environments like FedRAMP.”

To learn more about how Orca is focused on securing cloud environments and addressing cloud risks, visit the Orca Blog. Additionally, organizations interested in trialing the Orca Platform can sign up for a free, 30-day cloud risk assessment.

Availability
The integrated solution will be available in the second half of 2023.

About Orca Security
Orca Security is the pioneer of agentless cloud security that is trusted by hundreds of enterprises globally. Orca makes cloud security possible for enterprises moving to and scaling in the cloud with its patented SideScanning™ technology and Unified Data Model. The Orca Cloud Security Platform delivers the world's most comprehensive coverage and visibility of all risks across the cloud. With this continuous first-to-market innovations and expertise, the Orca Cloud Security Platform ensures security teams quickly identify and remediate risks to keep their businesses secure. Connect your first account in minutes: https://orca.security or take the free cloud risk assessment.

About ThreatOptix
ThreatOptix provides peerless server protection architected from the ground-up to defend Linux, with a technology that makes it easy for large enterprises and government agencies to detect, classify and mitigate threats with greater efficacy than any existing offering.

* ESG: The Maturation of Cloud-native Security 2021

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media
Emily Townsend
fama PR for Orca Security
orca@famapr.com

Kirtee Londhe Mehta
PR for ThreatOptix, Inc.
kirtee@threatoptix.ai

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye